SCHEMBL1127707

SCHEMBL1127707

CCOC(=O)C(Cc1ccc(Cl)cc1)c1ccccn1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.52
MEN1 O00255 1/20 0.52
GAA P10253 1/20 0.52
SMN1; SMN2 Q16637 1/20 0.52
GPR119 Q8TDV5 2/20 0.52
MME P08473 1/20 0.46
EPHX2 P34913 2/20 0.46
L3MBTL1 Q9Y468 2/20 0.44
MAPK1 P28482 1/20 0.44
KDM4E B2RXH2 2/20 0.44
ALDH1A1 P00352 2/20 0.44
MAPT P10636 2/20 0.43
LMNA P02545 2/20 0.43
NPSR1 Q6W5P4 2/20 0.43
TNF P01375 1/20 0.43
HSP90AA1 P07900 1/20 0.43
HPGD P15428 1/20 0.43
ALOX12 P18054 1/20 0.43
CCR6 P51684 1/20 0.43
RUNX1 Q01196 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1127390 0.90 KMT2A (0.48) KMT2AMEN1GAASMN1; SMN2GPR119
SCHEMBL1127424 0.89 MEN1 (0.57) KMT2AMEN1GAASMN1; SMN2GPR119
SCHEMBL1127513 0.85 KMT2A (0.50) KMT2AMEN1GAASMN1; SMN2GPR119
SCHEMBL1127873 0.84 MEN1 (0.49) KMT2AMEN1GAASMN1; SMN2GPR119
SCHEMBL3373228 0.84 KMT2A (0.45) KMT2AGAASMN1; SMN2MMEL3MBTL1
SCHEMBL1127590 0.82 KMT2A (0.46) KMT2AMMEL3MBTL1LMNANPSR1
SCHEMBL11532666 0.81 MEN1 (0.57) KMT2AMEN1GAASMN1; SMN2KDM4E
SCHEMBL1127494 0.81 KMT2A (0.51) KMT2AMEN1GAASMN1; SMN2GPR119
SCHEMBL1127316 0.80 MEN1 (0.52) KMT2AMEN1GAASMN1; SMN2GPR119
SCHEMBL1127447 0.79 KMT2A (0.49) KMT2AMEN1GAASMN1; SMN2L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2283002-A2 NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION Intermune, Inc. (US) 2011-02-16 EP disclosed
WO-2009134616-A2 NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION INTERMUNE, INC. (US) 2009-11-05 WO disclosed
WO-2009134616-A2 NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION INTERMUNE, INC. (US) 2009-11-05 WO disclosed
US-20090257979-A1 Novel Inhibitors of Hepatitis C Virus Replication INTERMUNE, INC. (US) 2009-10-15 US disclosed
US-20090257979-A1 Novel Inhibitors of Hepatitis C Virus Replication INTERMUNE, INC. (US) 2009-10-15 US disclosed
US-20090257979-A1 Novel Inhibitors of Hepatitis C Virus Replication INTERMUNE, INC. (US) 2009-10-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090257979-A1 Novel Inhibitors of Hepatitis C Virus Replication EIF2AK2, HAVCR2, HDGF KMT2A 2735/4885MEN1 4723/4885GAA 799/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.